Announcement PDF Annual Report 2023 Antisense Therapeutics Limited 41 095 060 745 30 June 2023 (Previous corresponding year: 30 June 2022) Name of entity ABN Year Ended Results for Announcement to the Market The results of Antisense Therapeutics Limited for the Year Ended 30 June 2023 are as follows: Revenues Loss after tax attributable to members Net Loss for the period attributable to members up up up 10.26% to (95.81)% to (95.81)% to 384,923 11,379,828 11,379,828 Explanation of Results The Company reported a loss for the full-year ended 30 June 2023 of $11,379,828 (30 June 2022: $5,811,810) including expenses relating to issue of options "share-based payments" of $214,053 (30 June 2022: $124,417). The loss is after fully expensing all research and development costs (including those related to the manufacture of clinical development supplies) deployed in successfully advancing the clinical development of ATL1102 for DMD to Phase IIB trial. For further details relating to the current period’s results, refer to the contained within this document. Dividends No dividends have been paid or declared by the Company since the beginning of the current reporting period. No dividends were paid for the previous reporting period. Net Tangible Assets Per Share Net tangible assets ($) Shares (No.) Net tangible assets per share (cents) Basic loss per share (cents) Diluted loss per share (cents) 2023 20,933,825 669,314,536 3.13 2022 21,141,439 668,793,978 3.16 2023 (1.70) (1.70) 2022 (0.92) (0.92) Net tangible are defined as net assets of the Company which include both Right-of-Use assets and corresponding lease liabilities as per the introduction from 01 July 2019, of AASB16: "Leases" Status of Audit of Accounts The Appendix 4E is based on accounts which have been audited. The audit report is included within the annual report which accompanies this Appendix 4E. Contents to Annual Report PAGE Letter from the Chair 1 Operations Report 2 Intellectual Property Report 7 Directors' Report 11 Auditor Independence Declaration 23 Corporate Governance 24 Statement of Profit or Loss and Other Comprehensive Income 25 Statement of Financial Position 26 Statement of Changes in Equity 27 Statement of Cash Flows 28 Notes to the Financial Statements 29 Directors' Declaration 50 Independent Auditor's Report 51 Corporate Information 57 B 2023 ANNUAL REPORT Letter from the Chair Dear Shareholders I begin this annual letter by acknowledging our ongoing shareholder support over the FY23, a year in which Antisense Therapeutics (ANP) has experienced significant change and seen positive progress, albeit against the challenging macroeconomic climate in 2023 where the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.073% while the broader ASX200 is up 6.6%. The ANP share price has not escaped the downward pressure on share price widely experienced across our sector. I am proud that even against this sobering backdrop, the ANP board and management team has stepped up delivering on a commitment to attracting high quality talent to meet our business challenges. I thank both our outgoing CEO Mark Diamond and Regulatory lead Nuket Desem for their prior efforts and welcome those that joined during FY 2023: Dr. Anthony Filippis, Chief Commercial Officer, our new clinical development lead Dr. Andrew McKenzie and incoming Managing Director and Chief Executive Officer Dr. James Garner who collectively bring a wealth of industry experience. I also wish to take this opportunity to offer my gratitude to fellow board members Drs Gary Pace (resigned Nov 2022) and Gil Price, for their valuable insights and contribution. Over the past year the Board provided guidance and input on strategy, key initiatives, and prudent capital management, directly enabling the progress of ATL1102 within our available financial means. Much was achieved during the year. Importantly financial stewardship of the Company remained strong. The cash position as of 30th June 2023 was $10,967 million. The increase in the Company’s activities, particularly for clinical trial preparation, raised annual expenditure. We will remain vigilant regarding cost control and maintaining a strong balance sheet to support our aspirations. On the research front, under the direction of Dr George Tachas, two studies to further understand the biological mechanism and clinical potential of ATL1102 were initiated, namely a) mouse study ATL1102 in combination with an antisense oligonucleotide (ASO) to CD49d and a dystrophin restoration agent for the treatment of Duchenne muscular dystrophy and b) a study to investigate the effects of an antisense oligonucleotide (ASO) to CD49d in a mouse model of dysferlin deficiency for the potential treatment of Limb Girdle Muscular Dystrophy R2. The results of these two studies, if translatable to the human condition, offer exciting new clinical opportunities which are under strategic consideration. dosing was commenced. These two events represented a significant effort by the ANP team and together are expected to significantly move the program forward. We are grateful to the clinical investigators, under the leadership of Principal Investigator, Professor Thomas Voit, and the advisors on our Data Safety Monitoring Board, chaired by Dr. Michaela Guglieri, for their support of ATL1102. We are indebted to the patients and their families already enrolled in the Phase IIb study and over the next year we will be enhancing our interactions with and support of the DMD patient advocacy groups. The next 12 to 18 months are potentially transformative for the company as we expect to report on the chronic toxicology study as well as the current clinical trial. These two events will define the path towards regulatory approval, and we will remain laser focused on delivering these milestones. Pivotal to our longer-term future is our ability to continue financially fund our programs. The emphatic support from our institutional investors and shareholders is encouraging but we appreciate the importance of relationships and collaborations with global pharmaceutical partners, and we look forward to being able to update the market on these efforts at the appropriate time. Our commitment to communicating with the market and our shareholders will continue. In addition to the mandatory company news disclosures, we will host webinars and webcasts and make more use of social media and face to face shareholder briefings to share our strategic plans. In conclusion, the company, with its experienced team and global high-quality investigator network is well positioned to perform and conduct its clinical trial program in DMD to ultimately provide a new, potentially life-changing treatment for the DMD community. Critical progress on advancing ATL1102 was also achieved during FY2023. Firstly, the nine-month chronic money toxicology study was initiated, an important step for continued clinical development under the regulatory jurisdiction of the FDA and secondly, the Phase IIb clinical study in non-ambulant boys with DMD was started and ANNUAL REPORT 2023 1 Operations Report Overview of Company’s Activities ATL1102 for Duchenne muscular dystrophy (DMD) Antisense Therapeutics Limited (“the Company” or “Antisense Therapeutics”) continued its focus on advancing its antisense oligonucleotide products under development. The following report on operations details the research and development activities undertaken by the Company in the period. The Company is undertaking clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). Duchenne muscular dystrophy (DMD) is an X-linked disease that affects 1 in 3600 to 5000 live male births (Bushby et al, 2010). DMD occurs as a result of mutations in the dystrophin gene which causes a defect in the protein or reduction or absence of the dystrophin protein. Children with DMD have dystrophin deficient muscles and are susceptible to contraction induced injury to muscle which triggers the immune system which exacerbates muscle damage (Pinto Mariz, 2015). Ongoing deterioration in muscle strength affects lower limbs leading to impaired mobility, and also affects upper limbs, leading to further loss of function and self-care ability. The need for wheelchair use can occur in early teenage years, with respiratory, cardiac, cognitive dysfunction also emerging. With no intervention, the mean age of life is approximately 19 years. The management of the inflammation associated with DMD is currently via the use of corticosteroids, which have insufficient efficacy and significant side effects. Partnership with Ionis Pharmaceuticals Inc. Antisense Therapeutics has world-wide exclusive licenses to use two antisense compounds (ATL1102 and ATL1103) for all disease indications via its partnership with Ionis Pharmaceuticals Inc (Ionis). As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform that has the potential to treat the untreatable. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading neurological and cardiometabolic franchises. The partnership with Ionis provides Antisense Therapeutics with access to Ionis antisense intellectual property and drug development expertise to facilitate the development and commercialization of the Company’s antisense compounds. In turn Ionis receives a share of product commercialization proceeds received by Antisense Therapeutics. ABOUT ATL1102 ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA4 expression has demonstrated activity in a number of animal models of inflammatory disease including asthma and MS with the MS animal data having been published in a peer reviewed scientific journal. ATL1102 was shown to be highly effective in reducing MS lesions in a Phase IIa clinical trial in RR-MS patients. The ATL1102 Phase IIa clinical data has been published in the medical Journal Neurology (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788). 2 2023 ANNUAL REPORT A key challenge in the management of DMD patients is to reduce the inflammation that exacerbates the muscle fibre damage. It has been reported in scientific literature that patients with DMD who have a greater number of T cells with high levels of CD49d (ATL1102's biological target) on their surface have more severe and rapid disease progression. ATL1102 is being developed as a novel treatment for the inflammation that exacerbates muscle fibre damage in DMD patients for which the current available treatment is corticosteroids. Corticosteroids have a range of serious side effects when used for a prolonged period as required in DMD. As a consequence, there is an acknowledged high need for new therapeutic approaches for the treatment of inflammation associated with DMD. The Company conducted an open label six-month dosing trial of ATL1102 in nine non-ambulant patients with DMD aged between 10 and 18 years at the neuromuscular centre of the Royal Children's Hospital (RCH) which operates the largest clinic in the southern hemisphere treating children with DMD. The Company announced the successful results of the ATL1102 Phase II DMD trial. The primary endpoint was met with confirmation of the drug’s safety and activity. Notably positive effects across a range of secondary endpoints of disease progression were also reported, supporting the ongoing clinical development of ATL1102 in DMD. Progress Phase IIb Clinical - ATL1102 in DMD The Company has now received approvals from the regulatory authorities in Turkey, Bulgaria, Australia and the UK. During the period, the Company announced that it had revised its clinical trial plans and intended to conduct a double-blind, placebo controlled six-month dosing trial of ATL1102 followed by a six-month open label phase (collectively the ‘Phase IIb’ trial) in non-ambulant boys with DMD. The primary endpoint of PUL2.0 will be assessed after six months of treatment. Recruitment has commenced and the and the first participant was randomised and dosed with ATL1102 or Placebo in Turkey on 06 June 2023. This first patient was enrolled by Professor Haluk Topaloglu MD, Yeditepe University Kosuyolo Hospital Istanbul, Turkey. The trial is expected to enrol 45 participants from multiple sites in Europe and Australia and will involve a six-month regimen of either placebo, 25 mg or 50 mg of ATL1102 once weekly via subcutaneous injection. Following this, participants will continue into a further sixmonth extension treatment period, with placebo patients randomised to either the 25 mg or 50 mg ATL1102 groups. Post period the Company released positive initial data from a Duchenne muscular dystrophy (DMD) mdx animal study investigating the potential for ATL1102 in combination with a dystrophin exon skipping restoration drug. The revised trial design brings forward the definitive reporting of unblinded and statistically analysed trial data following the completion of the initial randomized blinded six-month dosing period and has allowed for the opportunity to incorporate Australian sites alongside key trial centres in Europe. This provides the important benefit of continuity of working with Australian investigators who were involved in the conduct of the previous successful Phase II clinical trial of ATL1102 in DMD. The addition of Australian trial sites is expected to facilitate a significantly greater proportion of the trial costs as being eligible for the R&D tax incentive cash rebate, which should have a material impact on reducing the cash requirements for the conduct of the study. The new strategy allows the Company to confirm drug efficacy through the rigor of the placebo-controlled trial design so as to allow for discussion with regulators for potential fast tracking into registration phase or potential accelerated approval, pending trial outcomes. DMD combination therapy study The combination therapy of antisense oligonucleotide (ASO) to CD49d and the dystrophin restoration agent showed statistically significant effects on the specific maximum force of the extensor digitorum longus muscle and the eccentric muscle force remaining following induced damage to the muscle compared to saline control. The study results suggest the potential for ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in DMD patients. Further investigations are ongoing to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. A provisional patent application titled “Combination Compositions and Methods for Treatment of Muscular Dystrophy” has been filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Further investigations are ongoing with the assessment of muscle dystrophin levels and other cellular markers. ANNUAL REPORT 2023 3 Operations Report continued Long COVID-19 study The Company completed a successful world first Long COVID-19 study that identified novel blood markers as potential targets for the diagnosis and treatment of the neurological deficits of Long COVID e.g. brain fog measured using established memory tests. A subset of the study results have been included in a scientific publication pre-print. T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID Lavanya Visvabharathy, Barbara A. Hanson, Zachary S. Orban, Patrick H. Lim, Nicole M. Palacio, Millenia Jimenez, Jeffrey R. Clark, Edith L. Graham, Eric M. Liotta, George Tachas, Pablo Penaloza-MacMaster, Igor J. Koralnik. Recent scientific publications report that neurological symptoms remain a major feature of Long COVID with cognitive impairment identified in approximately a quarter of subjects at 12 months post SARS-CoV2 infection. Long COVID: major findings, mechanisms and recommendations, Hannah E. Davis, Lisa McCorkell, Julia Moore Vogel & Eric J. Topol – Nature Reviews Microbiology volume 21, pages133-146 (2023). The Company has continued exploring interest in licensing/commercialising our Long Covid-19 Intellectual Property (IP). Discussions include an ongoing diaogue with a diagnostic company on a potential development collaboration. Australian patent application 2023900242 was lodged in February entitled “Biomarkers and uses thereof” following discussions with the diagnostic company that continue. We continue to work collaboratively with Professor Koralnik and with his input and his team’s assistance have prepared a scientific manuscript on some of the key research findings for submission to a high impact scientific journal. We are also exploring other potential collaborations including with Research Institutes trialing new therapies for subjects with Neural Long Covid, with these groups expressing interest in accessing our IP for use as a companion diagnostic in the development of their potential treatments. Ongoing engagement with DMD community, investors and pharmaceutical companies The Company continued its communication and active engagement with key opinion leaders, patients advocacy groups, potential collaborators, investors and commercial partners as a key operational priority. During the period the Company presented and participated at the following events: • Broker, Institutional and Sophisticated Investor presentation – Melbourne, 13 July 2022 • Australian Equities Day Webinar – Singapore, 28 July 2022 • Collaboration with DMD Hub, United Kingdom on clinical trial site selection – August 2022, ongoing • US IR and Media engagements – August – September 2022 • Webinar overview of the ATL1102 for DMD Revised Clinical Plans announcement – 7 September 2022 • Jett Foundation – Duchenne Awareness Day – Sponsor – 7 September 2022 • US Institutional virtual roadshow – various dates October, November, December 2022 • US IR and Media engagements - October - December 2022 • Biotech & Medical Devices Webinar – Singapore, 3 November 2022 • Annual General Meeting Presentation – Melbourne, 17 November 2022 • Attendance at the JP Morgan Healthcare Week – San Francisco, USA, 9 – 11 January 2023 • US Institutional virtual roadshow – various dates January, February, March 2023 • Clinical Trial Presentation at the Duchenne Parent Project aps XX International Conference on Duchenne and Becker Muscular Dystrophy – 18 February 2023 • Biotech Day, Spark Plus – Singapore, 24 February 2023 • US IR and Media engagements – January – March 2023 • Presentation at Parent Project Muscular Dystrophy (PPMD) 9th Annual Conference (29 June to 1 July 2023) 4 2023 ANNUAL REPORT ATL1102 in ambulant DMD and fibrotic conditions Limb Girdle Muscular Dystrophy R2 (LGMDR2) There are no approved treatments for LGMDR2. Having successfully demonstrated target drug activity (reducing target and immune cell RNA in muscle) using an antisense oligonucleotide to CD49d (mouse equivalent of ATL1102) in a dysferlin mutation animal model , during the period the Company advanced its planning for a chronic mouse study to assess key disease progression endpoints. Mice with the dysferlin mutation and disease characteristics have been sourced via Jain Foundation in the US. In February 2023 the Company commenced the second phase of its study to investigate the effects of an antisense oligonucleotide (ASO) to CD49d in a mouse model of dysferlin deficiency. The chronic study will assess the longer duration treatment effects on disease progression endpoints, including reduction in muscle adipose levels. The study is being conducted in collaboration with the Murdoch Children’s Research Institute in Melbourne and the Jain Foundation in the USA, In this blinded and controlled study, mice are being treated for four months with results to follow mid-2023. LGMDR2, or dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene, leading to a reduction or absence of dysferlin protein levels in muscle fibers. To date, no treatments have proven to be beneficial in slowing LGMDR2 disease progression. Antisense Therapeutics' use of ATL1102 as a treatment for dysferlinopathy is covered in its patent application PCTAU2020/050445, which is directed at modifying muscle performance by reducing muscle adiposity. The Company expects to be eligible to apply for additional market exclusivity protection via Orphan Drug Designation in the US and Europe if the outcomes from this chronic study in the dysferlin deficient animal model are positive. The company is looking forward to the results of the follow-on study, which, if positive, could support advancement into a future clinical trial in patients with dysferlinopathy. In March 2023 the Company announced the start of the nine-month chronic monkey toxicology study of ATL1102 DMD. Successful completion of the toxicology study is expected to be the final requisite step for the US Food and Drug Administration (FDA) to allow dosing of ATL1102 for a term longer than 6 months in the US. Successful completion of the nine-month chronic monkey toxicology study should also allow the Company to apply for expedited program status with the FDA including Fast Track or potential Breakthrough Therapy designation. US FDA has already granted ATL1102 an Orphan Drug Designation and a Rare Pediatric Disease Designation for the treatment of DMD. The reporting of key study findings in 1H’24 is around the same time as the six-month dosing results from the ATL1102 in DMD Phase IIb clinical study are expected which could then allow the Company to share with FDA and other regulatory bodies a compelling data package encompassing the Phase IIb study clinical results along with the outcomes from the nine-month toxicology study for potential discussions with the regulators on accelerated regulatory pathways to registration. As of week, ending 30 June 2023, 16 (of 40) doses had been administered and tolerated. Dosing of all animals is on track to be completed by December 2023 with study outcomes expected to be reported in the first half of 2024. Successful completion of the toxicology study is necessary for the FDA to allow dosing of ATL1102 for a term longer than six months in the US. ATL1102 Toxicology Study In the period the Company advised that it had initiated the process to conduct a nine-month chronic monkey toxicology study of ATL1102 at Contract Research Organisation (CRO) Pharmaron to support the advancement of the ATL1102 program in the US for Duchenne muscular dystrophy or any other clinical application of ATL1102. ANNUAL REPORT 2023 5 Operations Report continued Board & Management Following completion of the executive recruitment process undertaken by the Company following the AGM in 2022, the Board appointed Dr James Garner MBBS MBA as Chief Executive Officer (CEO) and Managing Director (MD). Dr Garner joined the Board as non-executive director on 8 May 2023 ahead of assuming the roles of Managing Director & CEO as of 7 August 2023. To ensure a smooth transition in the interim, Charmaine Gittleson assumed the role of Executive Chair. Non-Executive Director of the Company, Dr Gary Pace, retired from the Board of Directors following completion of his director term at the 2022 Annual General Meeting. The Company strengthened its leadership team with the appointment of Anthony Filippis as the Company’s Chief Commercial Officer in October 2022. R&D Tax Incentive In October 2022, the Company advised that it had received from the Australian Taxation Office an R&D Tax Incentive refund payment of $909,040 and in February 2023 the Company received a further $872,506. The amounts received were in relation to the expenditure incurred on eligible R&D activities undertaken in Australia & Overseas for the 2021/2022 financial year. Financial Position At 30 June 2023, the Company had cash reserves (including Term Deposits) of $10,967,259 (2022: $19,233,183). 6 2023 ANNUAL REPORT Events After The Balance Sheet Date Capital Raising & SPP On 18 July 2023, the Company announced it had raised $8.35m in an oversubscribed institutional placement under the company’s discretionary placement capacity in accordance with ASX Listing Rule 7.1 and 7.1A. The placement was substantially supported by the Company’s major shareholder, Platinum Asset Management, on behalf of Platinum International Health Care Fund and Platinum World Portfolios Plc - Platinum World Portfolios Health Sciences Fund, as cornerstone investor subscribing for $4 million as well as other institutional and sophisticated investors subscribing for the balance. In addition, on 21 August 2023 the Company announced it had raised $3.26m from a share purchase plan (SPP). The new funds facilitate advancing the ongoing international Phase IIb Clinical Trial ATL1102 program in Duchenne muscular dystrophy, as well as for ongoing working capital. In relation to the clinical program the funding will support all randomised patients receiving six months of treatment, with Placebo or 25 mg or 50 mg ATL1102, the primary efficacy and safety endpoint analysis, and the transition of the patients into the extension phase where they all receive a further six months of 25 mg or 50 mg ATL1102. Additionally, the funding will be applied to regulatory agency engagement, patient advocacy and corporate development interactions. Intellectual Property Report Antisense Therapeutics has 13 patent families with 39 patents registered and 29 patent applications filed pending examination covering its two antisense drugs ATL1102 and ATL1103 in their applications. Antisense Therapeutics also has additional to patents (and applications), orphan drug designation (ODD) for ATL1102 in DMD and ATL1103 in acromegaly in the US and Europe, with the potential to apply for ODD in other countries which upon registration of the drug would provide commercial exclusivity in the US and Europe and other countries.1 Since reporting on the status of the Company’s intellectual property portfolio in the 2022 Annual Report the Company has expanded its patent portfolio as follows: • Australian provisional application 2023900242 was filed covering combination compositions of ATL1102 and dystrophin exon skipping restoration drug in the treatment of DMD to protect the invention to 2044. • Canadian Patent 2,811,228 has been registered covering ATL1102 in reductions of circulating leukocytes covering applications including ATL1102 in the treatment of DMD to protect the invention to 2031. • International application PCT/AU2022/051129 was filed covering evaluating ATL1102 effects on plasma proteins (proteomics) in inflammation, fibrosis and muscle regeneration, for applications in new potential disease settings. • Australian patent 2016/051059 is now registered and European patent 16861126.7 has now been registered in France, Germany, Italy, Spain and the UK covering the use of ATL1102 for mobilizing leukemia cells in the treatment of acute myeloid leukemia (AML) to protect the invention to 2036. • US provisional applications 63/398350 and 63/398363 were filed covering methods of treating and treating plus diagnosing neurological post-acute sequelae (NPASC) of COVID-19. • Australian provisional application 2023900242 and US provisional application 63/398345 was filed covering biomarkers for use in the diagnosis of NPASC of COVID-19 to protect the invention to 2044. The progress outlined above has added important intellectual property to our portfolio. Patents have been registered for new applications and patent applications filed in countries in numerous regions of the globe to support Antisense Therapeutics commercialisation plans for its antisense drugs. Country Patent application or Patent No. Current Status Expiry ATL1103 Combination with Somavert Patents International PCT/AU2013/000095 National Phase Applications Australian 2013214698 Patent Registered 2033* Canada 2863499 Patent Registered 2033 Europe 13743020.3 Regional Phase – Granted. Patent registered in the 10 European countries below Denmark Patent Registered 2033* Finland Patent Registered 2033* France Patent Registered 2033* Germany Patent Registered 2033* Italy Patent Registered 2033* Spain Patent Registered 2033* Sweden Patent Registered 2033* Switzerland Patent Registered 2033* The Netherlands Patent Registered 2033* United Kingdom Patent Registered 2033* Japan 2014-555044 Patent Registered 2033* New Zealand 629004 Patent Registered 2033* ANNUAL REPORT 2023 7 Intellectual Property Report continued Country Patent application or Patent No. Current Status Expiry ATL1103 Combination with Somavert Patents continued USA 9,717,778 Patent Registered 2033* USA 9,821,034 Patent Registered 2033* ATL1103 Combination with Somatostatin agonist Patents International PCT/AU2014/000613 International Phase Australian 2014280847 Patent Registered 2034* Canada 2918787 Under Examination 2034 Europe 14810926.7 Regional Phase – Granted. Patent registered in the 10 European countries above to 2034* 2034* Japan 2016-518801 Patent Registered 2034* New Zealand 715825 Patent Registered 2034 USA 17/516543 Under Examination 2034* ATL1103 and serum IGF-I reduction Patents** USA 8,299,039 Patent Registered 2024** USA 7,846,906 Patent Registered 2024** ATL1103 GHBP reduction Patents USA 9,371,530 Patent Registered 2024** USA 9,988,635 Patent Registered 2024** ATL1102 MS Patent Portfolio** ATL1102 MS active brain lesion reduction Patents International PCT/US2009/003760 National Phase applications Australia AU 2009271678 Patent Registered 2029* Canada 2,728562 Patent Registered 2029 J